KEROS THERAPEUTICS INC (KROS)
US4923271013 - Common Stock
Taking everything into account, KROS scores 3 out of 10 in our fundamental rating. KROS was compared to 588 industry peers in the Biotechnology industry. While KROS has a great health rating, there are worries on its profitability. KROS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KROS had negative earnings in the past year.
In the past year KROS has reported a negative cash flow from operations.
In the past 5 years KROS always reported negative net income.
In the past 5 years KROS always reported negative operating cash flow.
1.2 Ratios
KROS's Return On Assets of -41.35% is in line compared to the rest of the industry. KROS outperforms 59.39% of its industry peers.
Looking at the Return On Equity, with a value of -46.05%, KROS is in the better half of the industry, outperforming 70.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.35% | ||
| ROE | -46.05% | ||
| ROIC | N/A |
ROA(3y)-32.82%
ROA(5y)-45.5%
ROE(3y)-35.98%
ROE(5y)-518.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KROS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KROS does not have a ROIC to compare to the WACC, probably because it is not profitable.
KROS has more shares outstanding than it did 1 year ago.
KROS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 30.69 indicates that KROS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 30.69, KROS belongs to the best of the industry, outperforming 94.88% of the companies in the same industry.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 30.69 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 14.25 indicates that KROS has no problem at all paying its short term obligations.
KROS has a Current ratio of 14.25. This is amongst the best in the industry. KROS outperforms 89.42% of its industry peers.
A Quick Ratio of 14.25 indicates that KROS has no problem at all paying its short term obligations.
KROS's Quick ratio of 14.25 is amongst the best of the industry. KROS outperforms 89.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.25 | ||
| Quick Ratio | 14.25 |
3. Growth
3.1 Past
KROS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.30%.
KROS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -56.77% yearly.
EPS 1Y (TTM)-25.3%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-22.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y-56.77%
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, KROS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.74% on average per year.
Based on estimates for the next years, KROS will show a very strong growth in Revenue. The Revenue will grow by 935.39% on average per year.
EPS Next Y-3.37%
EPS Next 2Y-3.62%
EPS Next 3Y-1.89%
EPS Next 5Y15.74%
Revenue Next Year164821%
Revenue Next 2Y141.18%
Revenue Next 3Y1768.18%
Revenue Next 5Y935.39%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
KROS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KROS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.62%
EPS Next 3Y-1.89%
5. Dividend
5.1 Amount
KROS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KEROS THERAPEUTICS INC
NASDAQ:KROS (5/3/2024, 7:02:33 PM)
After market: 60.57 0 (0%)60.57
+3.47 (+6.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.18B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.35% | ||
| ROE | -46.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 14.25 | ||
| Quick Ratio | 14.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-25.3%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-3.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y